Page last updated: 2024-09-05

erlotinib hydrochloride and nutlin-3a

erlotinib hydrochloride has been researched along with nutlin-3a in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (nutlin-3a)	Trials (nutlin-3a)	Recent Studies (post-2010) (nutlin-3a)
4,353	786	3,033	698	1	504

Protein Interaction Comparison

Protein	Taxonomy	nutlin-3a (IC50)
Protein Mdm4	Homo sapiens (human)	4.6273
Cellular tumor antigen p53	Homo sapiens (human)	1.0388
Cytochrome P450 2C19	Homo sapiens (human)	0.07
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	0.1832

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G	1
Brors, B; Haibe-Kains, B; Kurilov, R	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and nutlin-3a

Article	Year
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investigational new drugs, 2014, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53	2014
Assessment of modelling strategies for drug response prediction in cell lines and xenografts. Scientific reports, 2020, 02-18, Volume: 10, Issue:1 Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2020

Article

Year

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.

Investigational new drugs, 2014, Volume: 32, Issue:5

Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53

2014

Assessment of modelling strategies for drug response prediction in cell lines and xenografts.

Scientific reports, 2020, 02-18, Volume: 10, Issue:1

Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2020